Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 17 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Leveraging MCO Success to Elevate Portfolio Clubs to the International Stage
Brera Holdings (NASDAQ: BREA), an Ireland-based company focused on expanding a global portfolio of men’s…
-
QualityStocksNewsBreaks – Why Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) Is ‘One to Watch’
Silvercorp Metals (NYSE American: SVM) (TSX: SVM) is a Canadian mining company with a strong track…
-
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology,…